Table 1.

Overall efficacy of the HPV16/18 vaccine against oncogenic and oncogenic/nononcogenic HPV infections excluding types that the vaccine has shown evidence of efficacy against HPVs 6, 11, 16, 18, 31, 33, 45, 51, and 74^*

HPV infection	HPV		Control		Rate difference (95% CI)	Efficacy (95% CI), %
	No. of cases	Rate per 1000 infection-years (95% CI)	No. of cases	Rate per 1000 infection-years (95% CI)
Oncogenic HPV infection (types 35, 39, 52, 56, 58, 59, and 68/73)	5247	13.2 (12.7 to 13.7)	5842	14.8 (14.3 to 15.3)	1.6 (0.9 to 2.3)	10.8 (6.1 to 15.4)
Oncogenic or nononcogenic HPV infection (types 34, 35, 39, 40, 42, 43, 44, 52, 53, 54, 56, 58, 59, 66, 68/73, and 70)	9866	2.8 (2.4 to 3.1)	10548	3.0 (2.6 to 3.4)	0.2 (-0.3 to 0.7)	7.7 (-10.5 to 22.9)

^*CI = confidence interval; HPV = human papillomavirus.